Professor, Medicine, University of Miami School of Medicine
Oncology
Dr. Bach Ardalan, MD
|
|
Give Review
Bach Ardalan practices Oncology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Bach Ardalan is a published doctor. He has 79 publications published. The most current publication "Biomodulation of Fluorouracil in colorectal cancer." Bach Ardalan accepts all Medicare patients.
Publications
- Arsenic Attenuates GLI Signaling, Increasing or Decreasing its Transcriptional Program in a Context-Dependent Manner.
- In the War Against Solid Tumors Arsenic Trioxide Need Partners.
- Depth of Injury Caused by Liquid Nitrogen Cryospray: Study of Human Patients Undergoing Planned Esophagectomy.
- Influence of Treatment Modality in Outcomes for Different Stages of Resectable Esophageal AdenoCarcinomas.
- Does neoadjuvant chemotherapy improve outcomes for patients with gastric Cancer?
- In Vitro Global Gene Expression Analyses Support the Ethnopharmacological Use of Achyranthes aspera.
- The presence of three repeats in the 5'' UTR region of thymidylate synthase (TS) is associated with increased TS mRNA expression in cultured human Cancer cell lines in...
- A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated adv...
- 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed coloRectal carcinoma: a clinical experience.
- Anti-proliferative and anti-Cancer properties of Achyranthes aspera: specific inhibitory activity against pancreatic Cancer cells.
- Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal Cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
- Chronic exposure of colorectal Cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mec...
- A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed coloRectal carcinoma.
- Differential expression of Glut 1 mRNA and protein levels correlates with increased sensitivity to the glyco-conjugated nitric oxide donor (2-glu-SNAP) in different tu...
- Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal Cancer.
- Asymptomatic muscle metastases from esophageal adenoCarcinoma.
- A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal Cancer.
- Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic coloRectal carcinoma: a clinical experience.
- Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal Cancer.
- Esophageal Carcinoma: current controversial topics.
- A phase II trial of FUdR in patients with advanced pancreatic Cancer.
- A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal Cancer: a Southwest Oncology Grou...
- Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
- A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenoCarcinoma: a Southwest Oncol...
- Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
- Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatoCellular carcinoma-A phase II trial.
- Isolation of genomic DNA from human whole blood.
- A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver Cancer.
- Increased thymidylate synthase gene expression in liver metastases from coloRectal carcinoma: implications for chemotherapeutic options and survival.
- Biomodulation of Fluorouracil in colorectal Cancer.
- Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenoCarcinoma. A Southwest ...
- Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
- A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin.
- Radioimmunodetection of coloRectal carcinoma using technetium-99m-labeled Fab' fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody.
- A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatoCellular carcinoma.
- Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized ad...
- Phase II study of fluorouracil and its modulation in advanced colorectal Cancer: a Southwest Oncology Group study.
- A new complication of chemotherapy administered via permanent indwelling central venous catheter.
- Mechanism of resistance of variants of the Lewis lung Carcinoma to N-(phosphonacetyl)-L-aspartic acid.
- Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
- Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
- Prediction of clinical response to 5-fluorouracil-containing chemotherapy: preliminary results of in vitro assay in human breast Cancer.
- Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on Cell growth and ribonucleic acid synthesis in human mammary carcinoma.
- Radiometric enzyme-inhibition technique for measuring acivicin in plasma.
- Toxicologic effects of a high dose of thymidine in mice.
- Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man.
- Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia Cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihy...
- ReDuction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
- High-performance liquid chromatographic determination of 2-beta-D-ribofuranosylthiazole-4-carboxamide in urine and plasma.
- Determination of 3-deazaguanine in mice plasma by high-performance liquid chromatography.
- An update on the biochemistry of 5-fluorouracil.
- Mechanisms of sensitivity and resistance of murine Tumors to 5-fluorouracil.
- Phase I study of continuous-infusion PALA and 5-FU.
- Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
- The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man.
- Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenoCarcinomas.
- Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenoCarcinomas in vivo.
- Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats.
- Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.
- Phase I study of recombinant beta ser 17 interferon in the treatment of Cancer.
- Mechanism of action of a new antitumor agent, carbetimer.
- A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancrea...
- Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.
- Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant Cell lines.
- Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
- Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia.
- A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in coloRectal carcinoma.
- Carbetimer: a re-evaluation of a drug with a novel mechanism of action.
- Metastasis-induced acute pancreatitis.
- A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
- Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
- Phase II trial of mitoxantrone in head and neck Carcinoma.
- Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck Carcinoma.
- Splenic red Cell pooling in hairy Cell leukaemia.
- Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.
- Reduction of daunorubicin lethality and myocardial Cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
- Studies on mechanisms of 5-fluorouracil resistance in murine and human Tumors.
- Unusual cutaneous associations of a Malignant carcinoid tumour of the bronchus--erythema annulare centrifugum and white banding of the toe nails.
Schools
University College University Of London
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- AvMed
- Blue Card PPO
- Blue Care HMO
- NetworkBlue
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Employer Group Open Access HMO
- Employer Group PPO
- Emblem Health
- First Health (Coventry Health Care) PPO
- Golden Rule
- HealthPartners
- Choice Care PPO
- Preferred PPO
- Select HMO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Neighborhood Health Plan
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Neighborhood Health Partnership
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Hospital
-
University of Miami Hospital -
Miami Veterans Affairs Healthcare System
Drug Facts
| NPI NUMBER | 1356385140 | |
| NPPES Provider LastName | ARDALAN | |
| NPPES Provider FirstName | BACH | |
| NPPES Provider ZIPCode | 331361002 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1322.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 20.0 | |
| Percent Opioid Claims | 1.51 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356385140 |
| Last Name Of The Provider | ARDALAN |
| First Name Of The Provider | BACH |
| View All |
Similar Doctors
|
|
Dr. Jesus C. Fabregas Mercado, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Lisa D. Reale, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alan A. Lewin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Carlos Vidal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter J. Hosein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Serhan Alkan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khaled A. Tolba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tadeu F. Ambros, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Brown, MD |
|
|
Dr. Shweta Kurian, MD
This Doctor is OpenDoctor Recommended.
|